GlaxoSmithKline: antibody improves asthma control
(CercleFinance.com) - GlaxoSmithKline said on Monday that its monoclonal antibody Nucala (mepolizumab) improved asthma control compared with two other drugs.
The data, published in The Journal of Allergy and Clinical Immunology (JACI) today, showed that in patients with similar blood eosinophil counts, mepolizumab reduced clinically significant exacerbations by 34%-45% versus benralizumab across subgroups and by 45% versus reslizumab in another subgroup.
Asthma control was significantly improved with mepolizumab versus benralizumab, and versus reslizumab, GSK said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.
The data, published in The Journal of Allergy and Clinical Immunology (JACI) today, showed that in patients with similar blood eosinophil counts, mepolizumab reduced clinically significant exacerbations by 34%-45% versus benralizumab across subgroups and by 45% versus reslizumab in another subgroup.
Asthma control was significantly improved with mepolizumab versus benralizumab, and versus reslizumab, GSK said.
Copyright (c) 2018 CercleFinance.com. All rights reserved.